The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 No. 775

PART 12 U.K. Amendment of Part 12 (dealings with medicinal products)

Amendment of Schedule 17 (exemptions for sale, supply or administration by certain persons) U.K.

193.—(1) Schedule 17 M1 is amended as follows.

(2) In the table in Part 1, in column 1 in entry 10, [F1 for “marketing authorisations” substitute “UK marketing authorisations, EU marketing authorisations].

(3) In the table in Part 4, in columns 1 and 2 in entry 9, [F2 for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation].

Textual Amendments

F1 Words in reg. 193(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 147(a)

F2 Words in reg. 193(3) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 147(b)

Commencement Information

I1 Reg. 193 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Marginal Citations

M1 Schedule 17 was amended by S.I. 2014/1878, 2015/1503, 2016/186 and 2017/715,